Peptuvia

Cagrilintide vs Semaglutide

Cagrilintide and semaglutide are frequently mentioned in the same breath because they work through different satiety pathways — amylin versus GLP-1 — and are often studied as a pair rather than as rivals.

CagrilintideSemaglutide
Compound classLong-acting amylin analogGLP-1 receptor agonist
Primary targetAmylin / calcitonin receptorsGLP-1 receptor
CategoryGLP-1 & MetabolicGLP-1 & Metabolic
AdministrationWeekly subcutaneousWeekly subcutaneous
Research focusSatiety signaling (often paired with GLP-1)Appetite signaling & glycemic control

Key differences

  • Mechanism: cagrilintide is a long-acting amylin analog; semaglutide is a GLP-1 receptor agonist. They act on distinct satiety circuits.
  • Combination research: the two are commonly co-administered (the basis of the CagriSema research blend) for additive appetite-signaling effects.
  • Standalone profile: semaglutide has the larger standalone dataset; cagrilintide is more often studied as a complement.
  • Both are weekly subcutaneous compounds dosed in milligram fractions and titrated upward.

Which is right for your research?

These are complementary rather than competing compounds. Semaglutide is the GLP-1 backbone; cagrilintide is the amylin partner often layered alongside it in combination research.

Frequently asked questions

Do cagrilintide and semaglutide work the same way?

No. Cagrilintide is an amylin analog and semaglutide is a GLP-1 agonist. They influence satiety through different receptor pathways, which is why they are often combined.

Why are they studied together?

Because their mechanisms are complementary, combining an amylin analog with a GLP-1 agonist is researched for additive effects on satiety signaling.

Are they dosed similarly?

Both are weekly subcutaneous compounds titrated in fractional-milligram steps.

For Research Use Only. All products are sold as research chemicals for in-vitro laboratory study. Not for human consumption, medical, veterinary, or household use.